|
Oncological results
|
|
Adjuvant chemotherapy, n (%)
|
52 (26.0)
|
7 (24.1)
|
1 (10.0)
|
44 (27.3)
|
0.465
|
|
Recurrence, n (%)
|
|
Local
|
10 (5.0)
|
2 (6.9)
|
0
|
8 (5.0)
| |
|
Distance
|
34 (17.0)
|
3 (10.3)
|
0
|
31 (19.3)
|
0.170
|
|
Total patients with recurrence
|
39 (19.5)
|
4 (13.8)
|
0
|
35 (21.7)
| |
|
Time to recurrence (month), median ± IQR
|
10.7 (8.8–18.8)
|
7.0 (6.0–8.1)
|
0
|
11.8 (9.6–19.8)
|
0.173
|
|
Median of follow up (months) ± IQR
|
38.5 (17.2–65.6)
|
34.5 (17.1–66.5)
|
55.7 (28.8–61.9)
|
38.1 (16.7–65.5)
| |
|
Overall survival at 3 years
|
95.5%
|
82.9%
|
100%
|
94.7%
|
0.527
|
|
Overall survival at 5 years
|
91.5%
|
77%
|
100%
|
88.3%
|
|
Disease free survival at 3 years
|
81.5%
|
86.6%
|
100%
|
76%
|
0.480
|
|
Disease free survival at 5 years
|
80.5%
|
84%
|
100%
|
70%
|
|
Functional results
|
|
Permanent stoma, n (%)
|
31 (15.5)
|
13 (44.8)
|
3 (30.0)
|
15 (9.3)
|
< 0.001
|
|
Ileostomy
|
18 (9.0)
|
7 (24.1)
|
1 (10.0)
|
11 (6.8)
| |
|
Colostomy
|
13 (6.5)
|
6 (20.7)
|
2 (20.0)
|
4 (2.5)
| |
|
Other late complications, n (%)
| | | | |
< 0.001
|
|
Stenosis
|
24
|
6
|
1
|
17
| |
|
Hernia
|
16
|
5
|
4
|
7
| |
|
Occlusion
|
3
|
1
|
0
|
2
| |
|
Mean of quality of life assessments
|
|
LARS Score
|
26,2 ± 12,8
|
34,3 ± 4,0
|
28,8 ± 14,9
|
25,1 ± 13,0
|
0.522
|
|
Wexner Score
|
7,3 ± 4,8
|
10,3 ± 0,6
|
11,4 ± 3,8
|
6,4 ± 4,7
|
0.049
|
|
IIEF5
|
10,0 ± 8,9
|
18,0 ± 1,4
|
2,3 ± 2,3
|
10,4 ± 9,2
|
0.187
|
|
SF36
|
98,8 ± 10,5
|
105,0 ± 7,9
|
99,2 ± 5,4
|
98,2 ± 11,2
|
0.446
|
|
EORTC QLQ-C30
|
53,9 ± 11,4
|
49,3 ± 3,2
|
62,4 ± 14,5
|
53,0 ± 11,0
|
0.077
|
|
EuroQol
|
69,0 ± 18,9
|
75,0 ± 5,0
|
59,0 ± 18,2
|
69,9 ± 19,6
|
0.111
|
|
FIQL
|
86,8 ± 20,6
|
81,3 ± 3,5
|
74,2 ± 22,0
|
89,2 ± 20,8
|
0.136
|
|
EORTC QLQ-MY20
|
28,7 ± 7,0
|
28,3 ± 1,5
|
31,0 ± 7,1
|
28,4 ± 7,4
|
0.685
|
